Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas
Status:
Completed
Trial end date:
2019-04-02
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, multi-center, phase II trial of brentuximab vedotin to
evaluate ORR primarily in patients with EBV- and CD30-positive lymphomas.
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Seoul National University Bundang Hospital SMG-SNU Boramae Medical Center